GNCAQ — Genocea Biosciences Share Price
Last trade - 00:00- $0.00m
- -$12.49m
- $1.64m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | 0 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -267.1% | ||
| Return on Equity | -525.78% | ||
| Operating Margin | -2901.31% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 1.36 | 1.64 | n/a | n/a | 47.51% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Genocea Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens, that drive pro-tumor immune responses. Its GEN-009 is an investigational neoantigen vaccine delivering adjuvanted synthetic long peptides from ATLAS-identified neoantigens. The Company has a license agreement with Harvard College (Harvard), granting the Company a sublicensable license to one patent family, to develop, make, use, market licensed products, and perform licensed services related to the ATLAS discovery platform.
Directors
- Kenneth Bate NEC (70)
- William Clark PRE (53)
- Diantha Duvall CFO (49)
- Raymond Stapleton EVP (50)
- Jessica Flechtner CSO (49)
- Girish Aakalu OTH (46)
- Thomas Davis OTH (57)
- Ali Behbahani IND (44)
- Katrine Bosley IND (52)
- Jennifer Herron IND (51)
- Michael Higgins IND (58)
- George Siber IND (76)
- Last Annual
- December 31st, 2021
- Last Interim
- March 31st, 2022
- Incorporated
- August 16th, 2006
- Public Since
- February 5th, 2014
- No. of Shareholders
- 16
- No. of Employees
- 74
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 58,783,503
- Address
- 100 Acorn Park Drive, CAMBRIDGE, 02140
- Web
- http://www.genocea.com/
- Phone
- +1 6178768191
- Auditors
- Ernst & Young LLP
Upcoming Events for GNCAQ
Similar to GNCAQ
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
As of Today at 20:50 UTC, shares in Genocea Biosciences are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Genocea Biosciences last closed at $0.00 and the price had moved by -99% over the past 365 days. In terms of relative price strength the Genocea Biosciences share price has underperformed the S&P500 Index by -99.16% over the past year.
The overall consensus recommendation for Genocea Biosciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Genocea Biosciences does not currently pay a dividend.
Genocea Biosciences does not currently pay a dividend.
Genocea Biosciences does not currently pay a dividend.
To buy shares in Genocea Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Genocea Biosciences had a market capitalisation of $0.00m.
Here are the trading details for Genocea Biosciences:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: GNCAQ
Based on an overall assessment of its quality, value and momentum Genocea Biosciences is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genocea Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -99.09%.
As of the last closing price of $0.00, shares in Genocea Biosciences were trading -99.39% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Genocea Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Genocea Biosciences' management team is headed by:
- Kenneth Bate - NEC
- William Clark - PRE
- Diantha Duvall - CFO
- Raymond Stapleton - EVP
- Jessica Flechtner - CSO
- Girish Aakalu - OTH
- Thomas Davis - OTH
- Ali Behbahani - IND
- Katrine Bosley - IND
- Jennifer Herron - IND
- Michael Higgins - IND
- George Siber - IND